The advent of molecular profiling overcame the limitations of traditional solid tumor classification methods, which relied on the morphology of tumor cells and the surrounding tissue.1 Today, molecular profiling is a standard technique for classifying solid tumors, with established guidelines from the College of American Pathologists (CAP)2 and the National Comprehensive Cancer Network (NCCN).3
Tumor profiling using NGS analyzes a select set of genes, gene regions, or amplicons based on known involvement with solid tumors. This targeted approach delivers the high sensitivity to detect rare mutations and tumor subclones, offering increased visibility into important driver mutations in cancer.
Solid tumor profiling using NGS follows a simple workflow that can be easily scaled to hundreds of samples. Clinical research labs can go from DNA to report in approximately 40 hours. This workflow uses a single sequencing instrument, minimizing laboratory validation steps for seamless integration into the clinical research lab setting.
Clinical researchers at Avera Health use DNA and RNA sequencing to analyze solid tumors and uncover multiple drug-susceptible tumorigenic pathways. RNA-Seq is an essential part of their method, offering deeper insights into tumor biology.Read Interview
Illumina products empower clinical cancer research labs to use the most current technologies to find accurate answers while seamlessly integrating NGS into lab procedures. Library preparation kits are compatible with archival solid tumor tissues and can be easily scaled to process large sample volumes.
Illumina sequencers deliver industry-leading sequencing, generating ~90% of the world’s sequencing data.* Efficient reporting capabilities enable labs to annotate, classify, and communicate significant findings in a standard format.
Click on the below to view products for each workflow step.
Comprehensive panel detects single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression.TruSight Oncology UMI Reagents
The TruSight Oncology UMI Reagents and UMI Error Correction App reduce error rates in samples to ≤0.007%, enabling the detection of low frequency variants.TruSight Tumor 15
Focused panel to assess relevant solid tumor somatic variants in a simple, sample-to-data workflow.TruSight RNA Pan-Cancer
Targeting 1385 cancer-associated genes for gene expression, as well as variant and fusion detection in most oncology sample types including FFPE.TruSight RNA Fusion
A gene fusion detection panel targeting fusion associated genes in many cancer types with the ability to detect known and novel fusion gene partners.
Targeted research panel investigating hotspot regions of 50 genes with known associations to cancer.AmpliSeq for Ilumina Focus Panel
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.AmpliSeq for Illumina Comprehensive Panel v3
Targeted DNA and RNA research panel investigating variants across 161 genes associated with a range of cancer types.AmpliSeq for Illumina Comprehensive Cancer Panel
Targeted research panel investigating the exonic regions of 409 genes with known associations to cancer.
Simplest and most affordable solution for low-throughput targeted sequencing of solid tumors.MiSeq System
Desktop sequencer featuring a simple NGS workflow, integrated data analysis software, and unmatched accuracy.
Easy-to-use software for analysis and variant calling on the MiSeq System.VariantStudio Software
A powerful analysis and reporting tool that provides biological insight into genomic variant data.
* Data calculations on file. Illumina, Inc. 2015.